{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T09:29:57Z","timestamp":1745573397404},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40801-020-00199-3","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T13:02:43Z","timestamp":1593090163000},"page":"6-12","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies"],"prefix":"10.1007","volume":"7","author":[{"given":"Sandy","family":"Estrada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn S.","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Delaportas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"10","key":"199_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMp1500445","volume":"372","author":"SM Burwell","year":"2015","unstructured":"Burwell SM. Setting value-based payment goals: HHS efforts to improve US health care. N Engl J Med. 2015;372(10):897\u20139.","journal-title":"N Engl J Med."},{"key":"199_CR2","unstructured":"Centers for Medicare and Medicaid Services. Hospital Readmission Reduction Program 2018 [updated 12\/04\/2018 5:03 PM]. https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/Value-Based-Programs\/HRRP\/Hospital-Readmission-Reduction-Program.html."},{"key":"199_CR3","doi-asserted-by":"crossref","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51\u201377.","DOI":"10.1093\/cid\/ciw118"},{"key":"199_CR4","unstructured":"Joint Commission on Hospital Accreditation. Approved: new antimicrobial stewardship standard. Jt Comm Perspect. 2016;36(7)."},{"key":"199_CR5","unstructured":"US Department of Health and Human Services. Healthcare Cost Utilization Project HCUPnet\u2014principal diagnosis only restrict tables to non-neonatal, non-maternal discharges, outcomes by 197 skin and subcutaneous tissue infections 2019. https:\/\/hcupnet.qa.s-3.net."},{"issue":"3","key":"199_CR6","doi-asserted-by":"publisher","first-page":"A245","DOI":"10.1016\/j.jval.2015.03.1424","volume":"18","author":"GC Lee","year":"2015","unstructured":"Lee GC, Boyd NK, Lawson KA, Frei CR. PIN100: incidence and cost of skin and soft tissue infections in the United States. Val Health. 2015;18(3):A245.","journal-title":"Val Health"},{"key":"199_CR7","doi-asserted-by":"crossref","unstructured":"Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis. Hosp Pract. 2015;43(3):137\u201343.","DOI":"10.1080\/21548331.2015.1076325"},{"issue":"1","key":"199_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5811\/westjem.2014.11.24133","volume":"16","author":"DA Talan","year":"2015","unstructured":"Talan DA, Salhi BA, Moran GJ, Mower WR, Hsieh YH, Krishnadasan A, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med. 2015;16(1):89\u201397.","journal-title":"West J Emerg Med"},{"issue":"3","key":"199_CR9","doi-asserted-by":"publisher","first-page":"A203","DOI":"10.1016\/j.jval.2013.03.1025","volume":"16","author":"A Khachatryan","year":"2013","unstructured":"Khachatryan A, Ektare V, Xue M, Dunne M, Johnson KE, Stephens JM. Reducing total health care costs by shifting to outpatient (OP) settings of care for the management of Gram+ acute bacterial skin and skin structure infections (ABSSSI). Val Health. 2013;16(3):A203.","journal-title":"Val Health"},{"key":"199_CR10","doi-asserted-by":"crossref","unstructured":"Whittaker C, Nhan E, Ganapathiraju P, Garrett S, Reilly J, Travedi M. Expediting discharge in acute bacterial skin and skin structure infections: a clinical and economic comparison between Vancomycin and Oritavancin in hospitalized patients. Open Forum Infect Dis. 2018;5(Suppl 1):S118.","DOI":"10.1093\/ofid\/ofy210.299"},{"key":"199_CR11","unstructured":"Melinta Therapeutics, Inc. Orbactiv\u00ae (oritavancin): full prescribing information (package insert). New Haven: Melinta Therapeutics, Inc.; 2018."},{"issue":"1","key":"199_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","volume":"5","author":"KD Brade","year":"2016","unstructured":"Brade KD, Rybak JM, Rybak MJ. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections. Infect Dis Ther. 2016;5(1):1\u201315.","journal-title":"Infect Dis Ther"},{"key":"199_CR13","first-page":"217","volume":"8","author":"T O'Driscoll","year":"2015","unstructured":"O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217\u201330.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"199_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254\u201362.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"199_CR15","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180\u201390.","journal-title":"N Engl J Med"},{"key":"199_CR16","doi-asserted-by":"crossref","unstructured":"Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. Open Forum Infect Dis. 2017;4(1):ofw274.","DOI":"10.1093\/ofid\/ofw274"},{"issue":"4","key":"199_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/0018578717746415","volume":"53","author":"D Co","year":"2018","unstructured":"Co D, Roebuck L, VanLandingham J. Evaluation of oritavancin use at a community hospital. Hosp Pharm. 2018;53(4):272\u20136.","journal-title":"Hosp Pharm"},{"key":"199_CR18","doi-asserted-by":"crossref","unstructured":"Redell M, Moeck G, Lucasti C, Durso S, Kennedy C, Fusaro K, et al. A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis. 2018;5(6):ofy051.","DOI":"10.1093\/ofid\/ofy051"},{"key":"199_CR19","doi-asserted-by":"crossref","unstructured":"Whittaker C, Nhan E, Ganapathiraju P, Garrett S, Reilly J, Trivedi M. Expediting discharge in acute bacterial skin and skin structure infections: a clinical and economic comparison between vancomycin and oritavancin. Presented at: ID Week; 2018 Oct 3\u20137; San Francisco, CA, USA.","DOI":"10.1093\/ofid\/ofy210.299"},{"key":"199_CR20","unstructured":"Turner E, Estrada S, Galli A, Armstrong S, Delaportas D. Treatment of acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: clinical and economic outcomes from a real-world multi-center study of oritavancin. Poster No.1855. ASHP Conference for Pharmacy Leaders. Chicago, IL, USA. October 17\u201318, 2016. https:\/\/melintamedicalinformation.com\/Media\/Publications\/ORBACTIV\/ASHP%202016\/Turner%20EJ%20Poster%20241855%20ASHP%202016.pdf."},{"key":"199_CR21","unstructured":"Wolters Kluwer Clinical Drug Information, Inc. Medi-Span Price Rx: Oritavancin. https:\/\/pricerx.medispan.com\/."},{"key":"199_CR22","unstructured":"Premier Inc. Premier Healthcare Database White Paper: Data that informs and performs. Charlotte: Premier Inc.; 2018."},{"key":"199_CR23","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost Utilization Project: Clinical Classifications Software (CCS) for ICD-9-CM. 2019. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp."},{"key":"199_CR24","unstructured":"US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring: Center for Drug Evaluation and Research; 2013."},{"key":"199_CR25","unstructured":"Estrada S, Delaportas D, El-Imad B, Stanley J. Real-world experience utilizing oritavancin to discharge patients with ABSSSI (poster 20). Presented at: Making a Difference in Infectious Diseases (MAD-ID); 2016 May 5\u20137; Orlando, FL, USA."},{"key":"199_CR26","doi-asserted-by":"crossref","unstructured":"Lee G, Boyd N, Lawson K, Frei C. Incidence and cost of skin and soft tissue infections in the United States. Val Health. 2015;18(3):A245.","DOI":"10.1016\/j.jval.2015.03.1424"},{"issue":"9","key":"199_CR27","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/jac\/dks193","volume":"67","author":"M Dryden","year":"2012","unstructured":"Dryden M, Saeed K, Townsend R, Winnard C, Bourne S, Parker N, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012;67(9):2289\u201396.","journal-title":"J Antimicrob Chemother"},{"key":"199_CR28","doi-asserted-by":"crossref","unstructured":"Suaya JA, Mera RM, Cassidy A, O'Hara P, Amrine-Madsen H, Burstin S, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis. 2014;14:296.","DOI":"10.1186\/1471-2334-14-296"},{"key":"199_CR29","doi-asserted-by":"crossref","unstructured":"Kaye KS, Patel DA, Stephens JM, Khachatryan A, Patel A, Johnson K. Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact. PLoS ONE. 2015;10(11):e0143276.","DOI":"10.1371\/journal.pone.0143276"},{"issue":"12","key":"199_CR30","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3111\/13696998.2015.1078339","volume":"18","author":"V Ektare","year":"2015","unstructured":"Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015;18(12):1092\u2013101.","journal-title":"J Med Econ"},{"issue":"6","key":"199_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1001\/jamadermatol.2018.4650","volume":"155","author":"JM Fisher","year":"2019","unstructured":"Fisher JM, Feng JY, Tan SY, Mostaghimi A. Analysis of readmissions following hospitalization for cellulitis in the United States. JAMA Dermatol. 2019;155(6):720\u20133.","journal-title":"JAMA Dermatol"},{"key":"199_CR32","doi-asserted-by":"crossref","unstructured":"Sulham K, LaPensee K, Fan W, Lodise TP. Severity and costs of acute bacterial skin and skin structure infections by treatment setting: an application of the Eron classification to a real-world database. Val Health. 2014;17(3):A282.","DOI":"10.1016\/j.jval.2014.03.1642"},{"issue":"10","key":"199_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/1469-0691.12632","volume":"20","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Eckmann C, Lawson W, Stephens JM, Macahilig C, Solem CT, et al. Pan-European early switch\/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect. 2014;20(10):993\u20131000.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"199_CR34","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1128\/AAC.02626-15","volume":"60","author":"SJ Eells","year":"2016","unstructured":"Eells SJ, Nguyen M, Jung J, Macias-Gil R, May L, Miller LG. Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections. Antimicrob Agents Chemother. 2016;60(5):2941\u20138.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-020-00199-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T09:46:24Z","timestamp":1667123184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-020-00199-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":34,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["199"],"URL":"https:\/\/doi.org\/10.1007\/s40801-020-00199-3","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"25 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study and manuscript preparation were not funded. This manuscript is part of a supplement wholly funded by Melinta Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"TPL is a consultant and speaker for Melinta Therapeutics. GT has received consulting fees from Melinta Therapeutics, Summit plc, Spero Therapeutics, Shionogi Inc., and KBP Biosciences. DD is a speaker for Melinta Therapeutics and received a grant from The Medicines Company. SE has no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"IRB approval was given by Lee Health System (Fort Myers, FL) and Mons General Hospital (Morgantown, WV), and the study has been performed in accordance with the ethical standards of the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors had a role in study design and in conceiving and writing the manuscript. According to the guidelines of the International Committee of Medical Journal Editors (ICMJE,ExternalRef removed), all authors met the criteria for authorship, and no deserving authors have been omitted.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}}]}}